Attenuation of nephritis in lupus-prone mice by thalidomide

Rheumatology (United Kingdom)

Volumn 51, Issue 12, 2012, Pages 2131-2140

  Lee, Sang Won ^a   Park, Yong Beom ^a   Yang, Jaeseok ^b   Park, Kyu Hyung ^a   Lee, Soo Kon ^a   Choi, Kyu Hun ^a   Kim, Beom Seok ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

LN; NZB WF1 mice; Thalidomide

Indexed keywords

COMPLEMENT COMPONENT C3; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; GLOMERULONEPHRITIS; IMMUNE COMPLEX DEPOSITION; IMMUNOFLUORESCENCE TEST; KIDNEY TUBULE DAMAGE; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOTHERAPY; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL RATE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGEN-ANTIBODY COMPLEX; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MICE; MICE, INBRED NZB; MYCOPHENOLIC ACID; PREDNISOLONE; PROTEINURIA; SURVIVAL RATE; THALIDOMIDE;

EID: 84870325735     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes227     Document Type: Article

References (37)

1. Gordon C, Jayne D, Pusey C et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009;18:257-63.
2. Tesar V, Hruskova Z. Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol 2011;7:96-109.
3. Bertsias G, Ioannidis JP, Boletis J et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205.
4. Quach H, Ritchie D, Stewart AK et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22-32.
5. Majumdar S, Lamothe B, Aggarwal BB. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002;168: 2644-51.
6. Szekanecz Z, Besenyei T, Paragh G, Koch AE. Angiogenesis in rheumatoid arthritis. Autoimmunity 2009; 42:563-73.
7. Yang PT, Xiao WG, Qin L et al. A pilot study on changes of macrophage colony stimulating factor and transforming growth factor beta1 in male patients with ankylosing spondylitis taking thalidomide. Ann Rheum Dis 2010;69: 781-2.
8. Direskeneli H, Ergun T, Yavuz S, Hamuryudan V, Eksioglu-Demiralp E. Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease. Clin Rheumatol 2008;27:373-5.
9. Ito T, Ando H, Handa H. Teratogenic effects of thalidomide: molecular mechanisms. Cell Mol Life Sci 2011;68: 1569-79.
10. Delforge M, Bladé J, Dimopoulos MA et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11: 1086-95.
11. Tsukinoki T, Sugiyama H, Sunami R et al. Mesangial cell Fas ligand: upregulation in human lupus nephritis and NF-kappaB-mediated expression in cultured human mesangial cells. Clin Exp Nephrol 2004;8:196-205.
12. Zheng L, Sinniah R, Hsu SI. Pathogenic role of NF-kappaB activation in tubulointerstitial inflammatory lesions in human lupus nephritis. J Histochem Cytochem 2008;56: 517-29.
13. Neubert K, Meister S, Moser K et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14:748-55.
14. Lee SW, Kim BS. Comparison of therapeutic efficacy between bortezomib and combination treatment of prednisolone and mycophenolate mofetil on nephritis in NZB/WF1 mice. Clin Exp Rheumatol 2010;28:393-6.
15. Walchner M, Meurer M, Plewig G, Messer G. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol 2000;39: 383-8.
16. Vilanova M, Ribeiro A, Carneiro J, Arala-Chaves M. The effects of thalidomide treatment on autoimmune-prone NZB and MRL mice are consistent with stimulation of the central immune system. Scand J Immunol 1994;40:543-8.
17. Palumbo A, Bertola A, Falco P et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004;5:318-24.
18. Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9.
19. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006;203:553-61.
20. Postó l E, Meyer A, Cardillo F et al. Long-term administration of IgG2a anti-NK1.1 monoclonal antibody ameliorates lupus-like disease in NZB/W mice in spite of an early worsening induced by an IgG2a-dependent BAFF/BLyS production. Immunology 2008;125:184-96.
21. Liu Z, Bethunaickan R, Huang W et al. IFN-a confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice. J Immunol 2011;187:1506-13.
22. van der Vlag J, Berden JH. Lupus nephritis: role of antinucleosome autoantibodies. Semin Nephrol 2011;31: 376-89.
23. Zheng L, Sinniah R, Hsu SI. In situ glomerular expression of activated NF-kappaB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy. Virchows Arch 2006;448:172-83.
24. Weckerle CE, Imbuka D, Franek BS et al. Large scale analysis of tumor necrosis factor alpha levels in systemic lupus erythematosus. Arthritis Rheum 2012, Apr 5. doi:10.1002/art.34483. [Epub ahead of print].
25. Nakajima M, Kawahara S, Sakagami Y et al. Immunogold labelling of cytokines in glomeruli in children with various renal diseases. Nephron 1999;83:132-8.
26. Takemura T, Yoshioka K, Murakami K et al. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch 1994;424:459-64.
27. Zhu L, Yang X, Ji Y et al. Up-regulated renal expression of TNF-alpha signalling adapter proteins in lupus glomerulonephritis. Lupus 2009;18:116-27.
28. Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev 2012;11:321-5.
29. Kontoyiannis D, Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 2000;30:2038-47.
30. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989;52:421-34.
31. Segal R, Dayan M, Zinger H, Mozes E. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNF alpha monoclonal antibody and by pentoxiphylline. Lupus 2001;10:23-31.
32. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2: 875-94.
33. Gieseler F. Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. Thromb Haemost 2008;99: 1001-7.
34. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
35. Mak A, Cheak AA, Tan JY et al. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology 2009; 48:944-52.
36. Enghard P, Langnickel D, Riemekasten G. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis. Scand J Rheumatol 2006;35: 209-16.
37. Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F. Overexpression of interleukin-12 and T helper predominance in lupus nephritis. Clin Exp Immunol 2008;154:247-54.